Pharmaceutical ProductCached Profile
TULSA PRO
Active Ingredients (Generic):Unmapped
LIFETIME PROMOTIONAL SPEND
$0
General Payments Aggregated (2021–2025)
Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.
FDA Patient Safety Profile
Dynamic safety indicators compiled from official FDA product labels.
Active Clinical Trials
Clinical studies listing this drug as an active intervention.
Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-guided Transurethral Ultrasound Ablation for Localized Prostate Cancer
ACTIVE_NOT_RECRUITINGPhase NANCT03814252
Comparison Of Clinical And Radiological Success Of Pulpotomy Treatments Performed With Proroot MTA, NeoPUTTY MTA, TheraCal PT In Primary Teeth
COMPLETEDPhase NANCT07260357
Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer
COMPLETEDPhase NANCT03350529
Magnetic Resonance Image (MRI) Guided High Energy Ultrasound for Focal Prostate Cancer Ablation
RECRUITINGPhase NANCT04808427
Top Funded Physicians (Cumulative)
Doctors receiving the highest aggregate promotional support for this product.
No physician payment records found.
Drug Marketing Payments Log
Federal registry records of promotional speaking, consulting, meals, and offsets.
Year:
2025
2025
2024
2023
2022
2021
Querying Open Payments Database
Fetching live CMS.gov records for TULSA PRO...